Opus Genetics, Inc.
IRDNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for IRD. That does not mean none is planned.
Get an email about IRD's next catalysts
Track Opus Genetics (IRD) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 1 past
IRD Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.14 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Low dose pilocarpine
Presbyopia
AAV8.hLCA5
LCA5
OPGx-RDH12
Leber Congenital Amaurosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Low dose pilocarpine | Phase 3 | Presbyopia | - | - |
AAV8.hLCA5 | Phase 2 | LCA5 | - | - |
OPGx-RDH12 | Phase 2 | Leber Congenital Amaurosis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Opus Genetics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Opus Genetics, Inc.'s (IRD) pipeline across Phase 3, Phase 2. Its lead program is Low dose pilocarpine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Opus Genetics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Opus Genetics, Inc. (IRD) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track IRD biotech catalysts?→
Add IRD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Opus Genetics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.